Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins

This article was originally published in The Tan Sheet

Executive Summary

Merck should have included risk findings from the VIGOR study when promoting Vioxx to physicians before the data was added to labeling, FDA Office of New Drugs Director John Jenkins told a congressional hearing May 5
Advertisement

Related Content

Opportunity Knocks For Supplements Pitched As Problem Solvers
Opportunity Knocks For Supplements Pitched As Problem Solvers
Opportunity Knocks For Supplements Pitched As Problem Solvers
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
Drug Watch Website Data Is Not For Use In Advertising, FDA Cautions
Drug Watch Website Data Is Not For Use In Advertising, FDA Cautions

Topics

Advertisement
UsernamePublicRestriction

Register

PS098173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel